Market research
GBT.PA Guerbet SA
PA EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 86M
- P/E ratio
- Not available
- Analyst target
- 7.7667
- Dividend yield
- Not available
- Beta
- 1.07
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- FR0000032526
- Market cap
- 86M
- P/E ratio
- Not available
- Analyst target
- 7.7667
- Dividend yield
- Not available
- Beta
- 1.07
About
About Guerbet SA
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; Ready-Box, a contrast media warmer; MRI accessories and consumables for diagnostic imaging; OptiProtect 3S, a suite of services and support solution; Conray/Cysto-Conray, an iothalamate meglumine injection contrast agent for CT; Micropaque/Microtrast, a barium sulfate contrast agent for CT; Optiray, an ioversol contrast agent for CT and Cath lab; Telebrix Gastro, a meglumine ioxitalamate contrast agent for CT; and Xenetix/ScanBag by Xenetix, an Iobitridol contrast agent for CT and Cath lab. In addition, it offers OptiBolus, which allows for a uniform vascular enhancement throughout the procedure; OptiOne, a single head injector; OptiVantage Multi-use, an optimal power injector for X-ray procedures; OptiVantage, a dual-head CT contrast delivery injector; Illumena Néo, a multi-mode contrast delivery injector; Lipiodol Ultra Fluid, an iodinated ethyl ester of fatty acids of poppy seed oil; Qitexio, a range of lipiodol resistant medical devices consisting of medical syringes and a stopcock; Lipiodol Ultra Fluid for use in interventional radiology and women's health; and Patent Blue V, a pharmaceutical drug for breast cancer. The company was founded in 1901 and is headquartered in Villepinte, France.
Research context
Guerbet SA appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the GBT.PA discussion.
5 years, 6 months ago
Guerbet SA is currently in a long term downtrend where the price is trading 7.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.5.
Guerbet SA's total revenue sank by 0.0% to $207M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $9M since the same quarter in the previous year.
Finally, its free cash flow fell by 40.6% to $30M since the same quarter in the previous year.
Based on the above factors, Guerbet SA gets an overall score of 1/5.